Business
Adia Nutrition Announces Submission of Final Revised Protocol for Lower Back Pain Study with AdiaVita
Adia Nutrition Announces Submission of Final Revised Protocol for Lower Back Pain Study with AdiaVita.
About this update from Adia Nutrition, Inc.
[{"type":"text","content":"\r\n\r\n \r\n \r\n Adia Nutrition Announces Submission of Final Revised Protocol for Lower Back Pain Study with AdiaVita\r\n \r\n \r\n\r\n\r\nAdia Nutrition Announces Submission of Final Revised Protocol for Lower Back Pain Study with AdiaVita\r\n\r\n\r\n\r\nNewsfile Corp.\r\n\r\n\r\nNewsfile Corp\r\n\r\n\r\nWinter Park, Florida--(Newsfile Corp. - March 3, 2026) - Adia Nutrition Inc. (OTCQB: ADIA), a company focused on regenerative medicine and therapeutic solutions, today announced that its subsidiary, Adia Med of Winter Park, LLC, has submitted its final revised protocol to the Institutional Review Board (IRB) for the lower back pain clinical study.\r\n\r\n\r\nTo view an enhanced version of this graphic, please visit:\r\nhttps://images.newsfilecorp.com/files/10520/286105_img_8679_1.jpg\r\nFollowing the initial protocol submission on February 16, 2026, the IRB provided constructive feedback with positive comments on the overall study design and approach. The requested changes were minor in nature, primarily relating to refinements in study design details, patient safety measures, and outcome assessment parameters. Adia Med has incorporated these suggestions and submitted the final draft, which the Company believes addresses the IRB's input effectively and positions the protocol for approval.\r\nThe key features of the study remain consistent:\r\n\r\n A single-blind, placebo-controlled trial randomizing approximately 100 participants into two groups: one receiving AdiaVita via intravenous (IV) administration and the other receiving a placebo.\r\n Primary objective: To evaluate AdiaVita's potential to reduce inflammation and support repair of damaged tissue in the lower back.\r\n Crossover design: Following the initial three-month treatment period, participants in the placebo group will receive AdiaVita in the subsequent phase for additional within-subject data and extended follow-up.\r\n Non-invasive systemic delivery via IV infusion, intended as a less invasive alternative to conventional targeted injections.\r\n \r\nThe patient-pay model remains $5,000 per participant, with no additional cost for the crossover phase.\r\nThis development continues to build on the progress of Adia Med's IRB-approved 24-month Autism Spectrum Disorder (ASD) study (ClinicalTrials.gov NCT07304440), which is actively recruiting children aged 3-12 fro...